alatrofloxacin

Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer and delivered as a mesylate salt. It was approved in 1997 for intravenous use to treat serious bacterial infections, particularly in hospitalized patients. Alatrofloxacin acts as a prodrug that is rapidly converted in the body to trovafloxacin, which exerts the therapeutic effect. Its mechanism of action involves inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. Indications included nosocomial pneumonia, community-acquired pneumonia, complicated intra-abdominal infections (including post-surgical), gynecologic and pelvic infections (such as endomyometritis and septic abortion), and complicated skin/skin structure infections including diabetic foot infections caused by susceptible bacteria such as Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Bacteroides fragilis group organisms among others[1][2][4][8]. Alatrofloxacin was withdrawn from the U.S. market in 2001 due to safety concerns.

Brand names

Trovan

Other names

trovafloxacin prodrugalatrofloxacin mesylate